![Hakim Bouterfa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hakim Bouterfa
Chief Executive Officer at PentixaPharm GmbH
Hakim Bouterfa active positions
Companies | Position | Start | End |
---|---|---|---|
1717 Life Sciences Ventures GmbH | Private Equity Investor | 2016-12-31 | - |
PentixaPharm GmbH
![]() PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Chief Executive Officer | - | - |
Career history of Hakim Bouterfa
Former positions of Hakim Bouterfa
Companies | Position | Start | End |
---|---|---|---|
ECKERT & ZIEGLER SE | Chief Tech/Sci/R&D Officer | 2022-12-31 | 2023-12-30 |
Molecular Insight Pharmaceuticals GmbH
![]() Molecular Insight Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of Lantheus Holdings, Inc., Molecular Insight Pharmaceuticals GmbH develops and commercializes innovative molecular imaging pharmaceuticals. The company is based in Wuerzburg, Germany. | Chief Executive Officer | - | - |
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - | - |
OctreoPharm Sciences GmbH
![]() OctreoPharm Sciences GmbH Pharmaceuticals: MajorHealth Technology OctreoPharm Sciences GmbH develops and manufactures pharmaceutical products. It operates as a clinical development biopharmaceutical company which focuses on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company was founded by Hakim Larbi Bouterfa and Udo Blaseg in 2010 and is headquartered in Berlin, Germany. | Founder | 2008-12-31 | - |
Statistics
International
Germany | 6 |
Austria | 2 |
Operational
Chief Executive Officer | 2 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 5 |
Finance | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ECKERT & ZIEGLER SE | Health Technology |
Private companies | 5 |
---|---|
OctreoPharm Sciences GmbH
![]() OctreoPharm Sciences GmbH Pharmaceuticals: MajorHealth Technology OctreoPharm Sciences GmbH develops and manufactures pharmaceutical products. It operates as a clinical development biopharmaceutical company which focuses on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company was founded by Hakim Larbi Bouterfa and Udo Blaseg in 2010 and is headquartered in Berlin, Germany. | Health Technology |
Molecular Insight Pharmaceuticals GmbH
![]() Molecular Insight Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of Lantheus Holdings, Inc., Molecular Insight Pharmaceuticals GmbH develops and commercializes innovative molecular imaging pharmaceuticals. The company is based in Wuerzburg, Germany. | Health Technology |
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. | Health Technology |
1717 Life Sciences Ventures GmbH | Finance |
PentixaPharm GmbH
![]() PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Commercial Services |
- Stock Market
- Insiders
- Hakim Bouterfa
- Experience